GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for En...
28 Abril 2021 - 9:00PM
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the
Group”), a world leader in discovering, developing and
commercialising regulatory approved cannabis-based medicines,
announces that it has received the Queen’s Award for Enterprise
2021 in the Innovation category, recognising GW’s innovative and
ground-breaking work to harness cannabinoid science to create the
world’s first regulatory approved, prescription cannabis-based
medicines.
Since its inception in 1998, GW has successfully
navigated significant barriers to enable the development,
manufacture and commercialisation of regulatory approved
cannabis-based medicines, leading the way in improving the lives of
patients and families around the world. Globally, GW has invested
more than £1.3 billion in the research, development and
infrastructure needed to bring novel, innovative medicines to
patients. With the majority of its staff located in the UK, GW
employs more than 1,100 employees globally, all of whom strive
every day to bring new, clinically proven medicines to patients
experiencing significant unmet need.
“We are honoured to receive such a prestigious
award for British businesses. When Dr Brian Whittle and I founded
GW 23 years ago, our mission was to improve the lives of seriously
ill patients by unlocking the potential of the cannabis plant
through rigorous scientific investigations and extensive clinical
trials in order to obtain regulatory approval for such medicines to
benefit patients,” said Dr Geoffrey W Guy, GW Founder and Chairman.
“Much of what is known about the medical uses of cannabis was
discovered by GW. We have led the way in understanding cannabinoid
science and how, if harnessed correctly and taken through the
regulatory approval pathway, it has the potential to improve the
lives of patients and their families. Today, I want to thank every
employee, clinician, researcher, patient and caregiver for helping
advance and achieve that mission.”
GW’s Chief Executive Officer Justin Gover said,
“Thanks to two decades of perseverance, dedication and pioneering
work, GW has established a world-leading position in cannabinoid
science and brought breakthrough medicines to patients in a new
frontier of medicine. We are immensely proud to have that work and
dedication recognised by the prestigious Queen’s Awards for
Enterprise. Our continued commitment to research and development
has resulted in the treatment of thousands of patients with our
medicines, and the prospect of helping countless more families
through our robust pipeline of early- and late-stage product
candidates.”
This award also recognises GW’s leadership in
cannabinoid science and efforts to benefit the wider medical
community, the pharmaceutical industry and society, as GW has shown
regulators and governments that it is possible to work within the
existing pharmaceutical regulatory system to develop clinically
proven medicines derived from the cannabis plant. In doing so, GW
has created a roadmap to approach the study, manufacture and
delivery of cannabis-based medicines, and supported regulators by
providing high-quality evidence to support the regulatory approval
of the company’s marketed medicines.
Regarded as the highest official UK award for
British business, the Queen’s Award for Enterprise is an annual
award which recognises outstanding achievement in Innovation. Now
in its 55th year, the Queen’s Award for Enterprise recognises
exceptional achievement by UK businesses. GW is one of several
organisations nationally to be recognised with a prestigious
Queen’s Award for Enterprise. It is awarded to products or services
that have been available on the market and can demonstrate
outstanding innovation and commercial success for at least two
years.
GW Pharmaceuticals would also like to pay
tribute to the significant role played by His Royal Highness The
Duke of Edinburgh in establishing Her Majesty’s Awards, and his
support of the Awards for the last 50 years. GW extends its deepest
sympathies to Her Majesty The Queen and the Royal Family.
ADDITIONAL INFORMATION
About GW Pharmaceuticals plcGW
Pharmaceuticals (GW), and U.S. subsidiary Greenwich Biosciences, is
a UK-based global biopharmaceutical company that has established a
world-leading position in cannabinoid science and medicine. Founded
over two decades ago in response to significant unmet patient need,
patients remain our key focus and improving their quality of life,
our motivation. GW’s pioneering work has led to the regulatory
approval of world first, potentially life improving, cannabis-based
medicines. Our continued dedication has resulted in the treatment
of thousands of patients with our medicines around the world. For
further information, please visit www.gwpharm.co.uk
About Queen’s Awards for
Enterprise The Queen’s Awards for Enterprise are the most
prestigious business awards in the UK. The awards were first
established in 1965 and since then over 7000 companies have
achieved a Queen’s Award.
The awards celebrate the success of exciting and
innovative businesses which are leading the way with pioneering
products or services, delivering impressive social mobility
programmes or showing their commitment to excellent sustainable
development practices.
This year 205 UK businesses have been recognised
for their contribution to International Trade, Innovation,
Sustainable Development and Promoting Opportunity (through Social
Mobility). 5 of these businesses won double awards.
The Queen’s Awards for Enterprise 2021
include:
- 122 awards for International
Trade
- 48 awards for Innovation
- 17 awards for Sustainable
Development
- 18 awards for Promoting Opportunity
(through Social Mobility)
The Queen’s Awards for Enterprise 2022 will be
open to applications from 1st May to 8th September 2021. Almost all
UK businesses (including non-profit) can apply, and the application
process is free. All applications must be made online, and you may
apply for more than one category. All entry forms, eligibility
criteria and information on how to apply is available here.
Enquiries |
All media enquiries |
publicrelations@gwpharm.com |
UK, EU and ex-U.S. media enquiries |
|
FTI Consulting |
|
Michael Trace / Ben Atwell |
+44 (0)203 727 1000 |
U.S. media enquiries |
|
Kristen Cardillo, Corporate Communications |
+1 760 579 6628 |
GW Pharmaceuticals (NASDAQ:GWPH)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024